The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 18)
Research Grant, 2017
The RESISTA-PD trial - The Effects of Resistant Starch on Bowel Habits, Short Chain Fatty Acids and Gut Microbiota in Parkinson Disease
Individuals with Parkinson's disease (PD) frequently suffer from constipation; those with PD also have altered bacterial composition in the gut. The RESISTA-PD trial investigates whether daily intake of a dietary supplement (resistant starch, provided as a water-soluble powder) can change gut bacteria composition and whether this supplement can improve bowel habits.
Researchers: Marcus M. Unger, MD
Therapeutic Pipeline Program, 2015
Constipation and gastroparesis (slow stomach emptying) are common non-motor symptoms of Parkinson's disease (PD). These symptoms cause troublesome gastrointestinal issues and can impair the absorption of and, response to, Parkinson's medications, such as levodopa. Unfortunately, there are FDA-approved treatments for slow stomach emptying in PD, and rigorously te...
Researchers: Leslie Jameleh Cloud, MD, MSc
Therapeutic Pipeline Program, 2013
The purpose of this study, called MOVE-PD, is to investigate how patients with Parkinson's disease (PD) and chronic constipation respond to the drug RM-131. The study will evaluate the safety and tolerability of the drug and evaluate whether RM-131 relieves constipation and related uncomfortable abdominal symptoms in patients who are unsatisfied with other therapie...
Researchers: Keith Gottesdiener, MD
Rapid Response Innovation Awards, 2012
The cause of Parkinson's disease is unknown and a reliable biomarker to identify Parkinson's disease patients as early as possible is urgently needed. Nerve cells near the nose and in the gut become first affected in Parkinson's disease and patients frequently suffer from loss of smell and constipation. The nose and gut harbor very high amounts of bacteria that influence our b...
Repositioning Drugs for PD, 2012
Improving Levodopa Bioavailability and Consistency of Absorption through Co-administration of GSK962040
Parkinson's disease (PD) often results in slower than normal emptying of food and medications from the stomach. This delayed gastric emptying is estimated to affect 50-90 percent of PD patients. Levodopa, the gold standard PD medication, is absorbed when it reaches the upper intestine. If gastric emptying is delayed, levodopa may be erratically absorbed, resulting in slower re...